Merck
CN
所有图片(1)

文件

安全信息

L6538

Sigma-Aldrich

Limaprost

≥99%, crystalline

登录查看公司和协议定价
所有图片(1)
别名:
11α,15S-Dihydroxy-17S,20-dimethyl-9-oxo-prosta-2E,13E-dien-1-oic acid, 17α,20-dimethyl-δ2-PGE1
经验公式（希尔记法）:
C22H36O5
CAS号:
74397-12-9
分子量:
380.52
MDL编号:
MFCD00868275
PubChem化学物质编号:
329817640
NACRES:
NA.77

质量水平

200

检测方案

≥99%

形式

crystalline

溶解性

DMF: soluble
DMSO: soluble
ethanol: soluble

运输

wet ice

储存温度

−20°C

SMILES字符串

CCCC[C@H](C)C[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCC\C=C\C(O)=O

InChI

1S/C22H36O5/c1-3-4-9-16(2)14-17(23)12-13-19-18(20(24)15-21(19)25)10-7-5-6-8-11-22(26)27/h8,11-13,16-19,21,23,25H,3-7,9-10,14-15H2,1-2H3,(H,26,27)/b11-8+,13-12+/t16-,17+,18+,19+,21+/m0/s1

InChI key

OJZYRQPMEIEQFC-UAWLTFRCSA-N

生化/生理作用

Limaprost exhibits cytoprotective, vasodilatory, and antiplatelet activity. Limaprost has the potential to treat lumbar spinal canal stenosis (LSCS) and several ischaemic symptoms of thromboangiitis obliterans (TAO).

其他说明

Potent analog of PGE1 with prolonged half-life.

象形图

Skull and crossbones
GHS06

警示用语：

Danger

危险声明

H300

预防措施声明

P264 - P301 + P310

危险分类

Acute Tox. 2 Oral

储存分类代码

6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保 在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503
货号
-
25G
包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务 寻求帮助

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

  • 如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。

  • 如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。

  • 如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

[Intracellular actions of antiplatelet drugs which affect cyclic AMP metabolism in platelets--their effects on Ca2+ mobilization and protein phosphorylation in human platelets].
M Nishikawa et al.
Rinsho byori. The Japanese journal of clinical pathology, Suppl 86, 54-61 (1990-07-01)
Kohji Hirata et al.
Cancer chemotherapy and pharmacology, 51(3), 216-220 (2003-03-26)
5-Fluorouracil (5-FU) causes intestinal mucosal damage and malabsorption. We have recently reported that coadministration of 17 S,20-dimethyl- trans- lower right triangle (2)-prostaglandin E(1) (OP-1206), a stable synthetic analogue of prostaglandin E(1), with 5-FU to rats protects the small intestine from
A Takeuchi et al.
International journal of clinical pharmacology research, 7(4), 283-289 (1987-01-01)
Prostaglandin E1 (PGE1) has been generally given only by intravascular injection. Recently, an oral PGE1 named OP1206 has been developed. OP1206 is a potent inhibitor of platelet aggregation as well as a strong vasodilator, and its half-life in humans is
T Ishizaki et al.
Japanese journal of medicine, 28(1), 34-40 (1989-01-01)
For the purpose of alleviating pulmonary hypertension and maintaining cardiac output, which tended to be decreased to acute low-flow oxygen therapy in chronic lung diseases, we evaluated combined low-flow oxygen therapy and oral administration of OP-1206, a prostaglandin E1 derivative
T Yamamoto et al.
Anesthesia and analgesia, 80(3), 515-520 (1995-03-01)
Nerve ischemia induces wallerian degeneration and peripheral neuropathy, the nerve constriction injury induces thermal hyperesthesia. Nerve ischemia is one possible mechanism in the development of thermal hyperesthesia in the nerve constriction injury model. Prostaglandin E1 increases tissue blood flow. In
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门